- Home
- BTCT vs IGC Comparison
BTCT vs IGC Comparison
Compare BTCT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTCT
- IGC
- Stock Information
- Founded
- BTCT 2006
- IGC 2005
- Country
- BTCT China
- IGC United States
- Employees
- BTCT N/A
- IGC N/A
- Industry
- BTCT Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BTCT Real Estate
- IGC Health Care
- Exchange
- BTCT Nasdaq
- IGC Nasdaq
- Market Cap
- BTCT 24.5M
- IGC 20.2M
- IPO Year
- BTCT N/A
- IGC N/A
- Fundamental
- Price
- BTCT $4.08
- IGC $0.29
- Analyst Decision
- BTCT
- IGC Strong Buy
- Analyst Count
- BTCT 0
- IGC 2
- Target Price
- BTCT N/A
- IGC $3.88
- AVG Volume (30 Days)
- BTCT 356.3K
- IGC 196.9K
- Earning Date
- BTCT 05-27-2025
- IGC 06-23-2025
- Dividend Yield
- BTCT N/A
- IGC N/A
- EPS Growth
- BTCT N/A
- IGC N/A
- EPS
- BTCT N/A
- IGC N/A
- Revenue
- BTCT $11,675,000.00
- IGC $1,236,000.00
- Revenue This Year
- BTCT N/A
- IGC N/A
- Revenue Next Year
- BTCT N/A
- IGC $16.45
- P/E Ratio
- BTCT N/A
- IGC N/A
- Revenue Growth
- BTCT 28.68
- IGC 1.65
- 52 Week Low
- BTCT $1.32
- IGC $0.25
- 52 Week High
- BTCT $26.58
- IGC $0.62
- Technical
- Relative Strength Index (RSI)
- BTCT 52.34
- IGC 46.51
- Support Level
- BTCT $3.85
- IGC $0.28
- Resistance Level
- BTCT $4.74
- IGC $0.32
- Average True Range (ATR)
- BTCT 0.37
- IGC 0.01
- MACD
- BTCT 0.04
- IGC -0.00
- Stochastic Oscillator
- BTCT 44.07
- IGC 26.50
About BTCT BTC Digital Ltd.
BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.